- Lobbying
- Lobbying by Amgen
Lobbying Relationship
Bills mentioned
H.R.1548: Pathway for Biosimilars Act
Sponsor: Anna G. Eshoo (D-Calif.)
H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act
Sponsor: Henry A. Waxman (D-Calif.)
H.R.1038: Access to Life-Saving Medicine Act
Sponsor: Henry A. Waxman (D-Calif.)
S.623: Access to Life-Saving Medicine Act
Sponsor: Charles E. Schumer (D-N.Y.)
H.R.1956: Patient Protection and Innovative Biologic Medicines Act of 2007
Sponsor: Jay Inslee (D-Wash.)
H.R.2900: Food and Drug Administration Amendments Act of 2007
Sponsor: John D. Dingell (D-Mich.)
S.1082: Food and Drug Administration Revitalization Act
Sponsor: Edward M. Kennedy (D-Mass.)
S.1145: Patent Reform Act of 2007
Sponsor: Patrick J. Leahy (D-Vt.)
H.R.1908: Patent Reform Act of 2007
Sponsor: Howard L. Berman (D-Calif.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Daniel Mattoon | n/a |
Daniel Mattoon Sr. | n/a |
Rebecca Gooding | n/a |
Ashley Clark | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate